MedTrace Logo

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

NCT01807520 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2018-03-13

Study results available
· View outcomes & findings →

Summary

This purpose of this study was to demonstrate the efficacy of secukinumab versus placebo on nail psoriasis and to assess long-term efficacy, safety and tolerability of secukinumab.

Conditions

  • Moderate to Severe Nail Psoriasis

Interventions

BIOLOGICAL

Secukinumab

Study treatment was provided in pre-filled 1 mL syringes.

BIOLOGICAL

Placebo

Placebo was provided in pre-filled 1 mL syringes.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-20
Primary Completion
2017-01-03
Completion
2017-01-03
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Czechia
  • Denmark
  • Germany
  • Greece
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01807520 on ClinicalTrials.gov